Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Kim

Gastroenterology Rockville, MD Medical Doctor

NPI 1366820409 CMS profile 1362527

15001 Shady Grove Rd Ste 300, Rockville, MD 20850

Open in the dashboard

General payments

$5,885

252 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Kim of Rockville, MD is reported in the CMS Open Payments database as having received $5,885 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,279 55
2024 General $1,500 64
2023 General $1,744 80
2022 General $1,031 43
2021 General $306 9
2020 General $26 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kim
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jeffrey Kim were reported at $1,279. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jeffrey Kim Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $26 $224 $74–$624 $114
2021 $306 $352 $106–$1,054 $132
2022 $1,031 $448 $129–$1,270 $149
2023 $1,744 $533 $150–$1,390 $160
2024 $1,500 $605 $160–$1,606 $164
2025 $1,279 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Cochlear Americas $642 6 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $606 32 payments
  3. Gilead Sciences, Inc. $570 7 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $539 35 payments
  5. Celgene Corporation $512 42 payments
  6. AbbVie, Inc. $485 23 payments
  7. Regeneron Healthcare Solutions, Inc. $370 17 payments
  8. Janssen Biotech, Inc. $249 12 payments
  9. Phathom Pharmaceuticals, Inc. $242 9 payments
  10. QOL Medical, LLC $209 7 payments
  11. Other $1,462 62 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,885 252 payments
Products named General payments · program years 2020–2025
  1. BAHA $642 6 payments
  2. XIFAXAN $621 36 payments
  3. ENTYVIO $548 28 payments
  4. ZEPOSIA $512 42 payments
  5. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $362 4 payments
  6. OSIA OSI300 IMPLANT $362 4 payments
  7. Vemlidy $359 3 payments
  8. DUPIXENT $305 14 payments
  9. Cochlear Implantable hearing solution $280 2 payments
  10. Cochlear Implantable hearing solution $280 2 payments
  11. Other $3,381 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

396

Median for Gastroenterology: 569

Drug cost

$11,907

Median for Gastroenterology: $104,976

Branded share of claims

29.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 62 $3,796
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 15 $2,573
Famotidine Generic 144 $1,811
Omeprazole Generic 54 $1,171
Pantoprazole Sodium Generic 68 $1,078
Sucralfate Generic 13 $930
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 40 $548

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$126,610

Of which drugs: $60,692

Medicare patients

281

Average age 74

Services billed

5,559

174 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 42%
Diabetes 32%
Ischemic heart disease 26%
Osteoporosis 21%
Chronic kidney disease 18%
Depression 17%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $190
  • GENZYME CORPORATION $24
$215 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $185
$185 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $181
$181 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $136
$136 — —
Vemlidy
  • Gilead Sciences, Inc. $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record